Form 4: Stoke Therapeutics' Chief Medical Officer, Barry Ticho, Reports Stock Option and Restricted Stock Unit Awards
SEC Form 4
Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On March 27, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, reported the acquisition of 60,000 employee stock options and 40,000 restricted stock units (RSUs).
- The stock options have an exercise price of $14.17 and vest monthly starting April 15, 2024, with the last vesting date on March 26, 2034.
- The RSUs vest annually beginning on March 15, 2025, with 1/4 of the total award vesting each year, contingent upon continued service to the issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and incentivizes management alignment with shareholder interests.
Positives
- The vesting schedule of both the stock options and RSUs incentivizes continued service and commitment from the Chief Medical Officer.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the Chief Medical Officer.
Industry Context
This filing is a routine disclosure of stock-based compensation for a company executive, common in the biotechnology industry to align management interests with shareholder value.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotechnology industry.
- Companies like Biogen, Vertex Pharmaceuticals, and Alnylam Pharmaceuticals also utilize similar equity-based compensation plans to attract and retain key personnel.
- The vesting schedules and amounts are generally in line with industry norms for executive compensation.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: acquisition of stock options and RSUs |
| 04/15/2024 | First vesting date for stock options (1/48 of total award) |
| 03/15/2025 | First vesting date for RSUs (1/4 of total award) |
| 03/26/2034 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.